Download PDF
Nervenheilkunde 2009; 28(08): 548-552
DOI: 10.1055/s-0038-1628674
Übersichtsarbeit
Schattauer GmbH

Pestwurz in der Behandlung der Migräne

Eine ÜbersichtPetasites in the treatment of migraineA review
S. Evers
1   Klinik und Poliklinik für Neurologie, Universitätsklinikum Münster
› Author Affiliations
Further Information

Publication History

Eingegangen am: 14 December 2008

angenommen am: 16 December 2008

Publication Date:
24 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Pestwurz wird in der Medizingeschichte seit der Antike als Heilpflanze bei verschiedenen Indikationen eingesetzt. In den letzten Jahren sind die biochemischen Mechanismen der Wirkung von Pestwurz teilweise aufgeklärt worden. Zuletzt hat sich klinisch insbesondere die Indikation Migräneprophylaxe durchgesetzt und ist mit den Verfahren der evidenzbasierten Medizin untersucht worden. Dabei hat sich in zwei Studien konsistent eine Wirksamkeit in der Migräneprophylaxe gezeigt. Der signifikante Unterschied zu Placebo in der Responderrate lag dabei zwischen 19 und 30%. Am häufigsten sind gastrointestinale Nebenwirkungen. Erhöhungen von Leberenzymen durch die Einnahme von Pestwurz sind kontrovers diskutiert worden. In placebokontrollierten Studien lag die Rate der reversiblen Leberwerterhöhungen unter 10%; in dem Melderegister der Nebenwirkungen sind bei geschätzten 75 000 Patientenjahren sechs Fälle eines möglichen oder wahrscheinlichen Zusammenhangs der Einnahme von Pestwurz und Lebererkrankungen dokumentiert.

Summary

Petasites has been used in the history of medicine since antiquity in different indications. In the past years, even some biochemical mechanisms of the therapeutic efficacy of petasites have been detected. In particular, migraine prophylaxis as an indication for petasites has been investigated in evidence-based trials. Two placebo controlled trials have shown consistently an efficacy of petasites in migraine prophylaxis. The significant difference to placebo was between 19 and 30% with respect to responder rate. The most frequent side effects of petasites are gastrointestinal complaints. Elevation of liver enzymes caused by petasites have been discussed controversy. In the placebo controlled trials, the rate of reversible elevation of liver enzymes was lower than 10%. In the register of all reported adverse events,six 6 cases of a liver disease with a possible or probable causal relationship to the intake of petasites have been documented.

Schlüsselwörter

Migräne - Pestwurz - Prophylaxe

Keywords

Migraine - petasites - prophylaxis
 

  • Literatur

  • 1 Aebi A, Waaler T, Buchi J. Petasin and S-petasin, the spasmolytic substances from Petasites officinalis L. Pharm Weekbl 1958; 93: 397-406.
    PubMedGoogle Scholar
  • 2 Barsom S. Behandlung von Koliken und Spasmen in der Urologie mit einem pflanzlichen Spasmolytikum. Erfahrungsheilkunde 1986; 35: 1-11.
    Google Scholar
  • 3 Bauer HW, Kühne P. Therapie von Harnleiterkoliken mit einem neuen Spasmoanalgetikum. Therapiewoche 1986; 36: 3756-3759.
    Google Scholar
  • 4 Bickel D. et al. Identification and characterization of inhibitors of peptido-leukotriene-synthesis from Petasites hybridus. Planta Med 1994; 60: 318-322.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Boehnke C. et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004; 11: 475-7.
    CrossrefPubMedGoogle Scholar
  • 6 Danesch U, Rittinghausen R. Safety of a patented special butterbur root extract for migraine prevention. Headache 2003; 43: 76-78.
    CrossrefPubMedGoogle Scholar
  • 7 De Weerdt CJ. et al. Herbal medicines in migraine prevention: randomized double-blind placebocontrolled crossover trial of a feverfew preparation. Phytomedicine 1996; 03: 225-230.
    CrossrefPubMedGoogle Scholar
  • 8 Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004; 51: 89-97.
    CrossrefPubMedGoogle Scholar
  • 9 Diener HC. et al. Efficacy and safety of 6.25 mg tid feverfew CO2-extract (MIG-99) in migraine prevention – a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25: 1031-1041.
    CrossrefPubMedGoogle Scholar
  • 10 Ernst E. Homeopathic prophylaxis of headaches and migraine? A systematic review. J Pain Symptom Manage 1999; 18: 353-357.
    CrossrefPubMedGoogle Scholar
  • 11 Esberg LB, Wang GJ, Lin YL, Ren J. Iso-S-petasin, a hypotensive sesquiterpene from Petasites formosanus, depresses cardiac contraction and intracellular Ca2+ transients in adult rat ventricular myocytes. J Pharm Pharmacol 2003; 55: 103-107.
    CrossrefPubMedGoogle Scholar
  • 12 Evers S. et al. EFNS guidelines on the drug treatment of migraine – report of an EFNS task force. Eur J Neurol 2006; 13: 560-572.
    CrossrefPubMedGoogle Scholar
  • 13 Evers S. et al. Akuttherapie und Prophylaxe der Migräne. Leitlinie der Deutschen Migräneund Kopfschmerzgesellschaft und der Deutschen Gesellschaft für Neurologie. Nervenheilkunde 2008; 27: 933-949.
    Google Scholar
  • 14 Facchinetti F. et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31: 298-301.
    CrossrefPubMedGoogle Scholar
  • 15 Fiebich BL. et al. Petasites hybridus extracts inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells. Planta Med 2005; 71: 12-19.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Gruia FS. Zur biologischen Schmerzbekämpfung. Ergebnisse einer Praxisstudie am Beispiel eines Phytotherapeutikums. Erfahrungsheilkunde 1986; 35: 396-401.
    Google Scholar
  • 17 Hershey AD. et al. Genomic abnormalities in patients with migraine and chronic migraine: preliminary blood gene expression suggests platelet abnormalities. Headache 2004; 44: 994-1004.
    CrossrefPubMedGoogle Scholar
  • 18 Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 1985; 291: 569-573.
    CrossrefPubMedGoogle Scholar
  • 19 Käufeler R, Meier B, Brattström A. Der PestwurzExtrakt Ze 339 – Wirkprinzipien und klinische Pharmakologie. In: Wildi E, Wink M. (eds)> Trends in medicinal plant research 2001. Romneya-Verlag, Dossenheim. 2001: 52-62.
    Google Scholar
  • 20 Ko W, Lei C, Lin Y, Chen C. Mechanisms of relaxant action of S-petasine and S-Isopetasin, sesquiterpenes of Petasites formosanus, in isolated guinea pig trachea. Planta Med 2001; 67: 224-229.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Kuritzky A. et al. Feverfew in the treatment of migraine: its effect on serotonin uptake and platelet activity. Neurology 1994; 44 Suppl (Suppl. 02) 293P.
    Google Scholar
  • 22 Lipton RB. et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63: 2240-2244.
    CrossrefPubMedGoogle Scholar
  • 23 Luo SF. et al. Induction of cyclooxygenase-2 by lipopolysaccharide in canine tracheal smooth muscle cells: involvement of p42/p44 and p38 mitogen-activated protein kinases and nuclear factor-kappaB pathways. Cell Signal 2003; 15: 497-509.
    CrossrefPubMedGoogle Scholar
  • 24 Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44: 885-890.
    CrossrefPubMedGoogle Scholar
  • 25 Murphy JJ, Heptinstall S, Mitchell JRA. Randomised doubleblind placebocontrolled trial of feverfew in migraine prevention. Lancet 1988; ii: 189-192.
    PubMedGoogle Scholar
  • 26 Oelkers-Ax R. et al. Butterbur root extract and music therapy in the prevention of childhood migraine: An explorative study. Europ J Pain 2008; 12: 301-313.
    Google Scholar
  • 27 Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 1997; 11: 508-511.
    CrossrefGoogle Scholar
  • 28 Peikert A. et al. Prophylaxis of migraine with oral magnesium: results from a prospective, multicenter, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-263.
    CrossrefPubMedGoogle Scholar
  • 29 Pfaffenrath V. et al. Magnesium in the prophylaxis of migraine – a double-blind, placebo-controlled study. Cephalalgia 1996; 16: 436-440.
    CrossrefPubMedGoogle Scholar
  • 30 Pfaffenrath V. et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis – a double-blind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22: 523-532.
    CrossrefPubMedGoogle Scholar
  • 31 Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004; (01) CD002286.
    PubMedGoogle Scholar
  • 32 Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 2005; 45: 196-203.
    CrossrefPubMedGoogle Scholar
  • 33 Rozen TD. et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002; 22: 137-141.
    CrossrefPubMedGoogle Scholar
  • 34 Sandor P. et al. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 2000; 40: 30-35.
    CrossrefPubMedGoogle Scholar
  • 35 Sandor PS. et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomised controlled trial. Neurology 2005; 64: 713-715.
    CrossrefPubMedGoogle Scholar
  • 36 Schoenen et al. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis – A randomized controlled trial. Neurology. 1998; 50: 466-470.
    PubMedGoogle Scholar
  • 37 Sheftell F. et al. Montelukast in the prophylaxis of migraine: a potential role for leukotriene modifiers. Headache 2000; 40: 158-163.
    CrossrefPubMedGoogle Scholar
  • 38 Straumsheim P. et al. Homeopathic treatment of migraine: a double blind, placebo controlled trial of 68 patients. Br Homeopath J 2000; 89: 4-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Amtliches Publikationsorgan der Swissmedic, Schweizerisches Heilmittelinstitut, Bern. Révocation de l’Autorisation de mise sur le marché (AMM) de certains médicaments contenant du pétasit. Swissmedic Journal 2004; 03 (01) 21.
    Google Scholar
  • 40 Teoh NC, Farrell GC. Hepatotoxicity associated with non-steroidal anti-inflammatory drugs. Clin Liver Dis 2003; 07: 401-413.
    CrossrefPubMedGoogle Scholar
  • 41 Thomet OA. et al. Differential inhibition of inflammatory effector functions by petasin, isopetasin and neopetasin in human eosinophils. Clin Exp Allergy 2001; 31: 1310-1320.
    CrossrefPubMedGoogle Scholar
  • 42 Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998; 18: 704-708.
    CrossrefPubMedGoogle Scholar
  • 43 Walach H. et al. Classical homeopathic treatment of chronic headaches. Cephalalgia 1997; 17: 119-126.
    CrossrefPubMedGoogle Scholar
  • 44 Wang GJ, Shum AYC, Lin YL. Calcium channel blockade in vascular smooth muscle cells: major hypotensive mechanism of S-petasine, a hypotensive sesquiterpene from Petasites formosanus. J Pharm Exp Ther 2001; 297: 240-246.
    Google Scholar
  • 45 Wang F. et al. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Headache 2003; 43: 601-610.
    CrossrefPubMedGoogle Scholar
  • 46 Whitmarsh TE. et al. Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. Cephalalgia 1997; 17: 600-4.
    CrossrefPubMedGoogle Scholar